Comparing Symptoms and Nerve Tests in Cancer Patients with Neuropathy
Author Information
Author(s): Vera Elisabeth Adreana Kleinveld, Miriam Emmelheinz, Daniel Egle, Magdalena Ritter, Wolfgang N. Löscher, Christian Marth, Corinne Gosewina Cornelia Horlings, Julia Wanschitz, Christine Brunner
Primary Institution: Medical University Innsbruck
Hypothesis
How do patient-reported symptoms of chemotherapy-induced peripheral neuropathy (CIPN) compare to neurophysiological findings?
Conclusion
The study found that subjective symptoms of CIPN did not correlate with nerve conduction study results, indicating that nerve tests may not be reliable for diagnosing CIPN.
Supporting Evidence
- 47.0% of patients reported symptoms compatible with CIPN at any follow-up.
- SNAP amplitudes were lower in patients who developed CIPN compared to those who did not.
- The overall diagnostic accuracy of nerve conduction studies for CIPN was low.
Takeaway
This study looked at cancer patients and found that what they say about their nerve pain doesn't always match what nerve tests show.
Methodology
Patients receiving taxane-based chemotherapy were followed for up to 9 months, with assessments of symptoms and nerve conduction studies at multiple time points.
Potential Biases
Potential bias due to the exclusion of patients with pre-existing neuropathy and the reliance on self-reported symptoms.
Limitations
Follow-up measurements were incomplete for many individuals, and the study included only female patients, limiting generalizability.
Participant Demographics
All participants were female cancer patients scheduled for taxane-based chemotherapy.
Statistical Information
P-Value
p<0.01
Statistical Significance
p<0.01
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website